Skye Bioscience, Inc. SKYE
1.67
(0.03)
(1.76%)
as of 25 Sep
- Market cap
- $7.5M
- P/E
- 0.0×
Follow SKYE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
4.77 | 3.30 | 1.78 | 0.95 |
Net Debt/EBITDA |
2.70 | 1.75 | 1.37 | 0.92 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.05 | 0.68 | 0.68 | 0.66 | |
Capex/Depreciation |
0.51 | 1.00 | 0.00 | 1.13 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(2.68) | (1.93) | (1.73) | (1.40) | |
Cash per Share |
7.12 | 5.19 | 3.45 | 2.03 | |
Shareholders Equity per Share |
6.62 | 4.04 | 1.82 | (0.10) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.62 | 4.04 | 1.82 | (0.10) | |
Free Cash Flow |
(13.27) | (9.59) | (8.56) | (6.94) | |
Working Capital |
31.56 | 18.89 | 8.16 | (0.57) | |
Capital Expenditures |
0.09 | 0.18 | — | 0.18 | |
Net Current Asset Value |
31.44 | 18.80 | 8.16 | (0.57) | |
| Other line items | |||||
Quick Ratio |
4.22 | 3.14 | 1.64 | 0.87 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.70) | (1.97) | (1.73) | (1.44) | |
Capex per Share |
0.02 | 0.04 | 0.00 | 0.04 | |
Average Payables |
1.80 | 1.30 | 2.83 | 3.75 | |
Average Assets |
61.43 | 50.54 | 42.10 | 31.60 | |
Average Common Equity |
54.32 | 44.09 | 34.13 | 21.59 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates